RxDoctor Payments Data

Michael Wanger, MD

Internal Medicine · Clearwater, FLNPI 1437101359

Payments from drug & device makers

$1,120in general payments, 2019–2025

Across 56 payments — averaging $20.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$230
  • GSK$222
  • Amgen$209
  • Pfizer$143
  • AbbVie$91
  • Johnson & Johnson$54
  • plus $172 from 8 others

What the payments were for

  • Food & beverage$1,120100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,120 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$634,142
Medicare patients
1,053
Services billed
8,992

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban214$217,062
OzempicSemaglutide89$105,302
XareltoRivaroxaban80$83,347
MounjaroTirzepatide57$82,953
JardianceEmpagliflozin46$61,116
FarxigaDapagliflozin Propanediol57$60,241
JanuviaSitagliptin Phosphate39$52,524
RybelsusSemaglutide25$45,353
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$25,069
MyrbetriqMirabegron23$21,609
Tresiba Flextouch U-100Insulin Degludec14$12,915
Bydureon BciseExenatide Microspheres12$11,538
Breo ElliptaFluticasone/Vilanterol20$11,348
Rosuvastatin Calcium660$9,430
Levothyroxine Sodium742$8,176

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$143$219,921240 claims
Novo NordiskOzempic, Rybelsus$230$150,655114 claims
Johnson & JohnsonXarelto$54$83,34780 claims
AstraZenecaFarxiga, Symbicort$20$64,63569 claims
GSKTrelegy Ellipta, Breo Ellipta$222$36,41742 claims
Astellas Pharma US IncMyrbetriq$22$21,60923 claims
AbbVieSynthroid$91$5,29181 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Clearwater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →